TherapeuticsMD reports third quarter 2026 results, notes new IMVEXXY milestone from Knight
The royalty company said Knight confirmed a 2025 sales milestone and later flagged a second milestone for 2026, while continuing to weigh strategic alternatives.
SEC filing